Fighting The High Cost Of Rx Drugs

AN INDUSTRY-WIDE TACTIC—At least eight of the top 10 drug makers have paid off their competition to block generics from entering the market. The FTC estimates that pay for delay deals cost consumers and taxpayers $3.5 billion every year in higher drug prices.

It's Time To End Pay For Delay

We all know prescription drugs cost too much. That’s partly because brand-name drug companies have been paying off generic drug makers to delay competition and keep prices high. This practice, called “pay for delay,” is commonplace in the pharmaceutical industry.
It's anti-competitive. It's hurting consumers. And it has to stop.

Competition is known to bring drug prices down 85-90 percent:

  • 30-day supply of the cholesterol drug Lipitor costs $194. The generic equivalent? Only $16.
  • The medication needed to prevent blood costs, Plavix, costs $205, while its generic equivalent is $13 for that same 30-day supply.
  • The antibiotic Cipro, used to treat a number of infections, costs $52; the generic costs $7.

And because drug companies can use pay for delay to maintain their strangle hold on the market long after their active-ingredient patents expire, consumers who rely on these drugs for their health are often forced to pay these higher prices for years before they see the generic.

CASE STUDY: Experts expected narcolepsy drug Provigil to go generic in 2006, but pay-for-delay deals kept the generic off the market until 2012. In the meantime, many multiple sclerosis patients had to pay over $1,200 each month for the drug, or manage without it. Bad news for consumers, but good news for the drug company. As the CEO of Cephalon, the drug company that makes Provigil, said about the deal, “We got six more years of patent protection. That’s $4 billion in sales that no one expected.”

Drug companies spend more on lobbying than any other industry. But if we build enough public support, we can stop the industry's pay-for-delay scheme and bring down drug and health care costs for consumers and taxpayers.

We're calling on Congress to put an end to pay for delay once and for all.

Issue updates

Report | Illinois PIRG Education Fund | Health Care

Ensuring Accountability

As our economy weakens nationwide, Illinoisans are having a harder time accessing and affording health insurance. Illinois needs to change the way it regulates the health insurance industry to make sure residents have access to predictable and affordable coverage. An analysis conducted by the Illinois Public Interest Research Group indicates that increasing cost-containment and accountability measures for health insurance companies does not mean that the premium costs paid by consumers will increase.

> Keep Reading
Report | U.S. PIRG Education Fund | Health Care

Health Care in Crisis

Unless the new Congress and Administration act to reduce health care costs, the yearly cost of the average employer-paid family health policy in America is projected to more than double from $11,381 in 2006 to $24,291 by 2016 even after adjusting for inflation. If recent trends continue, wages and household incomes will simply not keep up with these high costs.

> Keep Reading
Report | OSPIRG | Health Care

More For Your Money

Oregon businesses and consumers are facing unsustainable increases health insurance premiums and out-of-pocket costs, with health care costs rising at more than double the rate of inflation. Given this, Oregon officials are developing a major health reform plan to cut costs, improve health outcomes, and ensure Oregonians have access to affordable quality health care. The officials charged with this task, the Oregon Health Fund Board, released a draft reform plan for public comment in early September 2008.

> Keep Reading
Report | CALPIRG Education Fund | Health Care

Diagnosing the High Cost of Health Care

California spends billions of health care dollars on unnecessary treatments and services, administrative waste, and overpriced, sometimes harmful, medications. By finding ways to cut waste in its health care system and to reform an incentive structure that encourages overspending, California can reduce the burden that health care costs impose on our economy.

> Keep Reading
Report | CALPIRG | Health Care

Playing by Their Own Rules

Drug companies spend billions annually marketing their latest, most expensive drugs to doctors. These marketing efforts do not rely solely on scientific research and medical benefits, however; they employ a barrage of gifts, expensive meals, and wine-and-dine events to gain access to doctors. The result is that doctors looking for objective data about the efficacy and safety of pharmaceuticals are ensnared by this system, and find it increasingly easy to look to the drug companies for information.

> Keep Reading


View AllRSS Feed


Tell your senator that patients can't afford to wait another day. We need to end "Pay for Delay" right now.

Support Us

Your donation supports U.S. PIRG’s work to stand up for consumers on the issues that matter, especially when powerful interests are blocking progress.

Consumer Alerts

Join our network and stay up to date on our campaigns, get important consumer updates and take action on critical issues.
Optional Member Code